ArticleCureus2023
Superficial CD34-Positive Fibroblastic Tumor: A Case Series and a Review of Literature.
Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Superficial CD34-positive fibroblastic tumor (SCD34PFBT) is a recently recognized neoplasm of mesenchymal origin. Only a few cases have been reported in the literature so far. Microscopically, it consists of a dermal spindle cell neoplasm, with low mitotic activity, arranged in a fascicular pattern. The individual neoplastic cells show marked nuclear atypia, nuclear pseudo-inclusions, and dense eosinophilic cytoplasm. The tumor cells characteristically show positivity for CD34 immunohistochemical stain. This tumor behaves as a low-grade malignancy with potential to recur locally, with rare cases showing lymph node metastasis. Wide local excision and regular follow-up are the currently followed steps for management. This tumor serves as a diagnostic challenge due to its overt atypia, and it can be misdiagnosed as a sarcoma. Recognition of this entity among pathologists is important due to this reason. We hereby report four cases of this newly recognized entity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.